Document Detail


The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis.
MedLine Citation:
PMID:  8148487     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The long-term effects of tamoxifen on alterations in haemostasis which could lead towards thrombosis were investigated in 149 women who were disease-free for at least 5 years following mastectomy for breast cancer. All participants were randomized to receive tamoxifen as a post-surgical adjuvant treatment (89 patients, treated group) or not (60 patients, controls) for at least 2 years. 5.62% of the cases treated with tamoxifen suffered a venous thrombosis, while no thromboembolism was reported in the control group. No significant differences were observed between groups in the global clotting times, fibrinogen, fibrinolytic factors, or in the concentration of the main natural anticoagulants, antithrombin III (AT-III), protein C(PC) and protein S (PS). However, when the treated group was sub-divided, current users (n = 18) of the drug (median treatment duration 72 months) had significantly lower AT-III (P < 0.05) and PC (P < 0.05) activities, together with higher levels of plasminogen activity (P < 0.01) and tissue plasminogen activator antigen (P < 0.01), compared with 71 ex-users (who mostly received treatment for 2 years) and controls. We conclude that long-term treatment with tamoxifen for 2 or more years tends to reduce both AT-III and PC, a situation possibly predisposing towards thrombosis. Monitoring haemostasis in tamoxifen-treated breast cancer patients is therefore advisable.
Authors:
K D Pemberton; E Melissari; V V Kakkar
Related Documents :
18626347 - 500 consecutive patients with free tram flap breast reconstruction: a single surgeon's ...
23077447 - Evaluation of penile erection rigidity in healthy men using virtual touch tissue quanti...
12449347 - A clinical report of the effect of mechanical stress on functional results after fascie...
9598227 - Problems in wearing external prosthesis after mastectomy and patient's desire for breas...
10806987 - Progressive decrease of outflow gradient and septum thickness after percutaneous alcoho...
20111727 - Risk factors for treatment default among re-treatment tuberculosis patients in india, 2...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis     Volume:  4     ISSN:  0957-5235     ISO Abbreviation:  Blood Coagul. Fibrinolysis     Publication Date:  1993 Dec 
Date Detail:
Created Date:  1994-05-10     Completed Date:  1994-05-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9102551     Medline TA:  Blood Coagul Fibrinolysis     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  935-42     Citation Subset:  IM    
Affiliation:
Thrombosis Research Institute, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / metabolism*
Breast Neoplasms / drug therapy*,  metabolism
Chemotherapy, Adjuvant
Female
Fibrinolysis / drug effects*
Follow-Up Studies
Humans
Retrospective Studies
Tamoxifen / pharmacology*
Chemical
Reg. No./Substance:
0/Anticoagulants; 10540-29-1/Tamoxifen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence for thrombin binding to dermatan sulphate sites in the rabbit aorta subendothelium in vitro...
Next Document:  The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the i...